Concepedia

Maureen Cooper

MC

Statistics

Publications

23

Citations

1.8K

H-Index

17

Active since

1969

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Jet Propulsion Laboratory

Indiana Cancer Consortium

University of Rochester Medical Center

Community Cancer Center

Maureen Cooper is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, pharmacology, and oncology.

Publications per year

1969–2024

23

Publications

23

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

Jeffrey E. Lancet, Jörge E. Cortes, Donna E. Hogge et al. · Blood · 2014 · 336 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

A O’Farrell, James M. Foran, Walter Fiedler et al. · PubMed · 2003 · 311 citations

Medicine, Pharmacokinetics, Pharmacology +17

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

Francis J. Giles, Alison Stopeck, Lewis R. Silverman et al. · Blood · 2003 · 198 citations · Full text

Medicine, Oncology, Pharmacology +14

A Pilot Exploration of the Antiemetic Activity of Olanzapine for the Relief of Nausea in Patients with Advanced Cancer and Pain

Steven D. Passik, Jeremy Lundberg, Kenneth L. Kirsh et al. · Journal of Pain and Symptom Management · 2002 · 156 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma

Maurizio Zangari, Elias Anaissie, Alison Stopeck et al. · Clinical Cancer Research · 2004 · 116 citations

Medicine, Oncology, Pharmacology +17

1–5 of 23